Team compares effectiveness of four PD-L1 tests September 23, 2016 A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the “BLUEPRINT …